Nachrichten zur Protalix BioTherapeutics Aktie

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for...…

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company…

Market movers: Verizon, Sandisk, Protalix Biotherapeutics, American Express…

…

Protalix wins EU panel backing for expanded dosing of Fabry disease drug

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency’s human medicines committee has issued a positive...…

Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline

Protalix Biotherapeutics Inc (NYSE-A:PLX) on Monday shared an update from its CEO Dror Bashan, who highlighted the company’s strategic priorities…

Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development

Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has entered into a collaboration and option agreement with Secarna Pharmaceuticals to jointly...…

Protalix and Chiesi seek EMA re-examination of Elfabrio dosing opinion

Protalix Biotherapeutics Inc (NYSE-A:PLX) and Chiesi Global Rare Diseases said they have requested a re-examination of a recent negative opinion by…

Protalix, Chiesi reaffirm commitment to Fabry disease patients after EMA panel setback

Protalix Biotherapeutics Inc (NYSE-A:PLX) and Chiesi Global Rare Diseases said they remain committed to advancing treatment options for Fabry disease…

Protalix BioTherapeutics welcomes new finance chief

Protalix BioTherapeutics Inc (NYSE-A:PLX) has announced the appointment of Gilad Mamlok as senior vice president and chief financial officer, succeeding...…

Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution

Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has been added to the Russell 3000 and Russell 2000 Indexes, effective after…

Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth

Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout…

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline

Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the companys unique approach to drug manufacturing using plant...…

Protalix Biotherapeutics gains momentum: analysts see long-term upside

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio,…

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships,…

Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum

For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting…

Protalix Biotherapeutics gains momentum in the rare disease space: analysts

Protalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see…

Protalix BioTherapeutics Inc. (PLX): H.C. Wainwright sieht 533 % Kurspotenzial!

Protalix BioTherapeutics Inc. (PLX) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Herstellung von rekombinanten Proteinen zur Behandlung…

dpa-AFX ProFeed